Showing 101-110 of 7163 results for "".
Enstilar Approved; New Data for Otezla, Duac
https://practicaldermatology.com/topics/psoriasis/dermwiretv-enstilar-approved-new-data-for-otezla-duac/18687/LEO Pharma's Enstilar (Calcipotriene and Betamethasone Dipropionate) Foam, 0.005%/0.064% has been FDA-approved for plaque psoriasis. New data presented at EADV on Stiefel's Duac, Celgene's Otezla, and Boehringer Ingelheim's investigational biologic compound BI 655066. Plus, Galderma's OTC Excipial lThe State of Academic Dermatology
https://practicaldermatology.com/topics/practice-management/the-state-of-academic-dermatology/18843/In this edition of Derm Insider, host Neal Bhatia, MD sits down with Jane Grant-Kels, MD, Sheila Fallon Friedlander, MD, and Kevin Cooper, MD to discuss the challenges and rewards of academic dermatology. From meeting aggressive budgets to dealing with EMRs, academicians face many of the same demandBasal Cell Carcinoma in Skin of Color: Diagnosis and Treatment Considerations
https://practicaldermatology.com/topics/general-topics/basal-cell-carcinoma-in-skin-of-color-diagnosis-and-treatment-considerations/21177/BCC may be less common in more darkly pigmented skin, but it occurs, and diagnosis may be delayed. Appropriate treatment is crucial.DermwireTV — Bayer Buys Merck’s OTC Lines, Allergan Rejects Valeant Bid
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-mdash-bayer-buys-merck-rsquo-s-otc-lines-allergan-rejects-valeant-bid/19134/Bayer Purchases Merck's OTC Products and Allergan Rebuffs Valeant. This week DermWireTV explores Bayer's growth in the OTC space, including sunscreens, and reports new data on skin cancer mortality. Also in this edition: Neal Bhatia, MD reviews the Noah Worcester Society Annual Meeting.Assessing Dystrophic Nails: Finding the Cause
https://practicaldermatology.com/topics/general-topics/assessing-dystrophic-nails-finding-the-cause/21397/A podiatrist offers a unique perspective on the causes of dystrophic toenails.Rosacea Therapy: Current Approaches and Future Directions
https://practicaldermatology.com/topics/general-topics/rosacea-therapy-current-approaches-and-future-directions/21610/New topical formulations in development may become the first treatments approved for the reduction of erythema associated with rosacea.EHR Use in Dermatology: Where We Stand
https://practicaldermatology.com/topics/practice-management/ehr-use-in-dermatology-where-we-stand/21624/CMS released data for EHR use in 2011, but next year's data will likely determine the role EHRs will play in the future of dermatology.Adjusting to a Paradigm Shift in Documentation
https://practicaldermatology.com/topics/practice-management/adjusting-to-a-paradigm-shift-in-documentation/21681/Clinicians can navigate changing rules by selecting technologies that accommodate rapid shifts in documentation.Effectively Manage Older Patients with Skin Diseases
https://practicaldermatology.com/topics/psoriasis/effectively-manage-older-patients-with-skin-diseases/21749/As the population ages, staying abreast of the latest developments in geriatric dermatology is critical.Take 5: Developments Toward Improved Skin Cancer Detection and Treatment
https://practicaldermatology.com/columns/take-5/take-5-developments-toward-improved-skin-cancer-detection-and-treatment/21895/Here's an update on various studies and developments regarding the management of cutaneous malignancies.